(NP (NP (JJ Selective) (NNS effects)) (PP (IN of) (NP (NN DNA) (NN damaging) (NNS agents))) (PP (IN on) (NP (NP (NN HIV) (JJ long) (JJ terminal) (NN repeat) (NN activation)) (CC and) (NP (NP (NN virus) (NN replication)) (ADVP (FW in) (FW vitro))))) (. .))
(S (NP-SBJ (JJ Much) (NN attention)) (VP (VBZ has) (ADVP-TMP (RB recently)) (VP (VBN focused) (PP (IN on) (NP (DT the) (NN observation) (SBAR (IN that) (S (NP-SBJ (NN UV) (NN light)) (VP (MD can) (VP (VB activate) (NP (NP (NP (DT the) (JJ long) (JJ terminal) (NN repeat)) (PRN (-LRB- -LRB-) (NP (NN LTR)) (-RRB- -RRB-))) (PP (IN of) (NP (NP (DT the) (JJ human) (NN immunodeficiency) (NN virus)) (PRN (-LRB- -LRB-) (NP (NN HIV)) (-RRB- -RRB-))))))))))))) (. .))
(S (SBAR (IN Although) (S (NP-SBJ (NP (DT the) (NN mechanism)) (PP (IN of) (NP (NN LTR) (NN activation)))) (VP (VBZ remains) (ADJP-PRD (JJ obscure))))) (, ,) (NP-SBJ (NP (JJ several) (NNS lines)) (PP (IN of) (NP (NN investigation)))) (VP (VBP have) (VP (VBN suggested) (SBAR (IN that) (S (NP-SBJ (PRP it)) (VP (VBZ is) (NP-PRD (NP (DT a) (NN result)) (PP (IN of) (NP (NP (NN activation)) (PP (IN of) (NP (DT the) (NN NF-kappa) (NN B) (NN transcription) (NN factor) (-LRB- -LRB-) (NNS s) (-RRB- -RRB-))) (PP-TMP (VBG following) (NP (NP (NN signaling) (NNS events)) (ADJP (JJ related) (PP (TO to) (NP (VBN generalized) (NN DNA) (NN damage)))))))))))))) (. .))
(S (PP (IN In) (NP (DT this) (NN report))) (, ,) (NP-SBJ (PRP we)) (VP (VBP present) (NP (NP (NNS data)) (VP (NN demonstrating) (SBAR-COOD (SBAR (IN that) (S (NP-SBJ (NN HIV) (NN LTR) (NN activation)) (VP (VBZ is) (NP-PRD-COOD (RB not) (NP (NP (DT a) (JJ general) (NN consequence)) (PP (IN of) (NP (JJ cellular) (NN DNA) (NN damage)))) (, ,) (CONJP (CC but) (RB rather)) (NP (NP (DT a) (NN process)) (ADJP (JJ unique) (PP (TO to) (NP (JJ specific) (JJ genotoxic) (NNS stimuli))))))))) (, ,) (CC and) (SBAR (IN that) (S (NP-SBJ (PRP it)) (VP (VBZ does) (ADVP (RB not) (RB necessarily)) (VP (VB depend) (PP (IN on) (NP (NP (NN activation)) (PP (IN of) (NP (NN NF-kappa) (NN B))))))))))))) (. .))
(S (ADVP (RB Furthermore)) (, ,) (NP-SBJ (PRP we)) (VP (VBP demonstrate) (SBAR (IN that) (S (NP-SBJ (NP (JJ several)) (PP (IN of) (NP (DT these) (NNS agents)))) (VP (MD can) (ADVP (RB significantly)) (VP (VP-COOD (VP (VB increase) (NP (NN HIV) (NN replication))) (CC and) (VP (VB accelerate) (NP (JJ CD4-positive) (NN lymphocyte) (NN cytotoxicity)))) (ADVP (FW in) (FW vitro))))))) (. .))
(S (NP-SBJ (DT These) (NNS findings)) (, ,) (ADVP (RB therefore)) (, ,) (VP (MD could) (VP (VB have) (NP (JJ clinical) (NN significance)) (PP (TO to) (NP (NP (NN AIDS) (NNS patients)) (PP (IN with) (NP (NNS malignancies))) (SBAR (WHNP-81 (WP who)) (S (NP-SBJ (-NONE- *T*-81)) (VP (VBP are) (VP (VBG undergoing) (NP-COOD (NP (NN radiotherapy)) (CC and) (NP (NN chemotherapy))))))))))) (. .))
